This Article Figures Only Full Text Full Text (PDF) View Related Cardiosource Journal Scan Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Google Scholar Articles by Erlinge, D. Articles by Wallentin, L. Search for Related Content PubMed Articles by Erlinge, D. Articles by Wallentin, L. Related Collections Related Articles

CLINICAL RESEARCH: ANTIPLATELET THERAPY

Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo

David Erlinge, MD, PhD^_*,_*, Christoph Varenhorst, MD, Oscar Ö. Braun, MD, PhD^_*, Stefan James, MD, PhD, Kenneth J. Winters, MD, Joseph A. Jakubowski, PhD, John T. Brandt, MD, Atsuhiro Sugidachi, PhD^||, Agneta Siegbahn, MD, PhD and Lars Wallentin, MD, PhD

^_* Department of Cardiology, Lund University, Lund, Sweden
Uppsala Clinical Research Centre and Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Coagulation Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Lilly Research Laboratories, Indianapolis, Indiana
^|| Daiichi Sankyo Co., Ltd., Tokyo, Japan

Manuscript received April 28, 2008; revised manuscript received June 16, 2008, accepted July 10, 2008.

^_* Reprint requests and correspondence: Dr. David Erlinge, Department of Cardiology, Lund University Hospital, SE-221 85, Lund, Sweden (Email: david.erlinge{at}med.lu.se).

Objectives: We evaluated the prevalence and mechanism of poor responsiveness to clopidogrel and prasugrel in coronary artery disease patients with and without diabetes.

Background: Low platelet inhibition by clopidogrel is associated with ischemic clinical events. A higher 600-mg loading dose (LD) has been advocated to increase responsiveness to clopidogrel.

Methods: In this study, 110 aspirin-treated patients were randomized to double-blind treatment with clopidogrel 600 mg LD/75 mg maintenance dose (MD) for 28 days or prasugrel 60 mg LD/10 mg MD for 28 days. Pharmacodynamic (PD) response was evaluated by light transmission aggregometry and vasodilator-stimulated phosphoprotein phosphorylation. The PD poor responsiveness was defined with 4 definitions previously associated with worse clinical outcomes. Active metabolites (AM) of clopidogrel and prasugrel were measured. Clopidogrel AM was added ex vivo.

Results: The proportion of patients with poor responsiveness was greater in the clopidogrel group for all definitions at all time points from 1 h to 29 days. Poor responders had significantly lower plasma AM levels compared with responders. Patients with diabetes were over-represented in the poor-responder groups and had significantly lower levels of AM. Platelets of both poor responders and diabetic patients responded fully to AM added ex vivo.

Conclusions: Prasugrel treatment results in significantly fewer PD poor responders compared with clopidogrel after a 600-mg clopidogrel LD and during MD. The mechanism of incomplete platelet inhibition in clopidogrel poor-responder groups and in diabetic patients is lower plasma levels of its AM and not differences in platelet P2Y₁₂ receptor function.

Key Words: prasugrel • trials • thienopyridine • clopidogrel • platelets • clopidogrel resistance • coronary artery disease

Abbreviations and Acronyms   ADP = adenosine 5'-diphosphate   AM = active metabolite   AUC = area under the curve   LD = loading dose   LTA = light transmission aggregometry   MD = maintenance dose   MPA = maximal platelet aggregation   PCI = percutaneous coronary intervention   PD = pharmacodynamic   PRI = platelet reactivity index   RPA = residual platelet aggregation   VASP = vasodilator-stimulated phosphoprotein

Related Articles

The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy

John A. Cairns and John Eikelboom
J. Am. Coll. Cardiol. 2008 52: 1978-1980. [Full Text] [PDF]

This article has been cited by other articles:

				U. Stenestrand, S. K. James, J. Lindback, O. Frobert, J. Carlsson, F. Schersten, T. Nilsson, B. Lagerqvist, and for the SCAAR/SWEDEHEART study group Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) Eur. Heart J., November 10, 2009; (2009) ehp424v1. [Abstract] [Full Text] [PDF]

				R. P. Giugliano and E. Braunwald The Year in Non-ST-Segment Elevation Acute Coronary Syndrome. J. Am. Coll. Cardiol., October 13, 2009; 54(16): 1544 - 1555. [Full Text] [PDF]

				L. Wallentin P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use Eur. Heart J., August 2, 2009; 30(16): 1964 - 1977. [Abstract] [Full Text] [PDF]

				N. B Norgard, K. D Mathews, and G. C Wall Drug-Drug Interaction Between Clopidogrel and the Proton Pump Inhibitors Ann. Pharmacother., July 1, 2009; 43(7): 1266 - 1274. [Abstract] [Full Text] [PDF]

				J. A. Cairns and J. Eikelboom The Pursuit of Clinically Relevant Measures of Platelet Function After Antiplatelet Drug Therapy J. Am. Coll. Cardiol., December 9, 2008; 52(24): 1978 - 1980. [Full Text] [PDF]